Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer.
J Gastrointest Surg. 2024.
PMID: 39127404
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 0 |
Search Results
8 results
Results by year
Citations
2
articles
found by citation matching
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer.
J Gastrointest Surg. 2024.
PMID: 39271000
No abstract available.
Search results
Page 1
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer.
J Gastrointest Surg. 2024 Dec;28(12):2148-2149. doi: 10.1016/j.gassur.2024.09.008. Epub 2024 Sep 11.
J Gastrointest Surg. 2024.
PMID: 39271000
No abstract available.
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer.
J Gastrointest Surg. 2024 Nov;28(11):1745-1751. doi: 10.1016/j.gassur.2024.07.026. Epub 2024 Aug 9.
J Gastrointest Surg. 2024.
PMID: 39127404
BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by radical esophagectomy is the standard treatment for locally advanced esophageal squamous cell cancer (LA-ESCC). ...Of note, 3 different nCRT regimens were r …
BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by radical esophagectomy is the standard treatment for loc …
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Dis Esophagus. 2017 Jul 1;30(7):1-8. doi: 10.1093/dote/dox025.
Dis Esophagus. 2017.
PMID: 28475728
We retrospectively evaluated the long-term results of trimodality therapy for patients with locally advanced esophageal cancer treated on several chemotherapy regimens. Between 1999 and 2014, 215 patients with locally advanced …
We retrospectively evaluated the long-term results of trimodality therapy for patients with locally advanced esophag …
Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis.
Front Immunol. 2024 Dec 6;15:1478377. doi: 10.3389/fimmu.2024.1478377. eCollection 2024.
Front Immunol. 2024.
PMID: 39712027
Free PMC article.
BACKGROUND: The aim of this network meta-analysis was to clarify the efficacy and safety of different immune checkpoint inhibitors (ICIs) in combination with chemotherapy in the neoadjuvant phase for the treatment of locally advanced esophage …
BACKGROUND: The aim of this network meta-analysis was to clarify the efficacy and safety of different immune checkpoint inhibitors (I …
Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Int J Surg. 2024 Jan 1;110(1):490-506. doi: 10.1097/JS9.0000000000000816.
Int J Surg. 2024.
PMID: 37800587
Free PMC article.
BACKGROUND: The application of neoadjuvant immune checkpoint inhibitors combined with chemotherapy (NICT) in treating locally advanced oesophageal squamous cell carcinoma (ESCC) is a subject of considerable research interest. ...Nevertheless, additional rando …
BACKGROUND: The application of neoadjuvant immune checkpoint inhibitors combined with chemotherapy (NICT) in treating locally …
Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Thorac Cancer. 2023 Mar;14(7):700-708. doi: 10.1111/1759-7714.14795. Epub 2023 Feb 14.
Thorac Cancer. 2023.
PMID: 36788648
Free PMC article.
BACKGROUND: This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus platinum-based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable …
BACKGROUND: This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus pl …
Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.
Am J Surg Pathol. 2014.
PMID: 25140894
Free article.
Histopathologic determination of tumor regression provides important prognostic information for locally advanced gastroesophageal carcinomas after neoadjuvant treatment. Regression grading systems mostly refer to the amount of therapy-induced fi …
Histopathologic determination of tumor regression provides important prognostic information for locally advanced gastroesophag …
Microarray-based response prediction in esophageal adenocarcinoma.
Clin Cancer Res. 2010 Jan 1;16(1):330-7. doi: 10.1158/1078-0432.CCR-09-1673. Epub 2009 Dec 22.
Clin Cancer Res. 2010.
PMID: 20028767
PURPOSE: In locally advanced (uT(3), N(+)) adenocarcinomas of the esophagus, neoadjuvant chemotherapy improves patient outcome. ...All patients underwent neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and leucovorin and subsequent r …
PURPOSE: In locally advanced (uT(3), N(+)) adenocarcinomas of the esophagus, neoadjuvant chemotherapy improves patient …
Cite